Abstract
In a prospective randomized study, 53 patients with advanced gastric cancer previously untreated by chemotherapy were randomly assigned to treatment with 5-FU alone or combined with mitomycin and cytarabine (MFC). The response rate with MFC was higher (28%) than with 5-FU alone (21%). The difference, however, was not statistically significant. Median response duration was practically identical with 5-FU (16 weeks) and MFC (17 weeks). There was no difference in median survival between the two groups (39 and 43 weeks, respectively).
Publication types
-
Clinical Trial
-
Comparative Study
-
Randomized Controlled Trial
MeSH terms
-
Aged
-
Antineoplastic Combined Chemotherapy Protocols*
-
Cytarabine / administration & dosage*
-
Cytarabine / adverse effects
-
Drug Evaluation
-
Drug Therapy, Combination
-
Female
-
Fluorouracil / administration & dosage*
-
Fluorouracil / adverse effects
-
Humans
-
Male
-
Middle Aged
-
Mitomycin
-
Mitomycins / administration & dosage*
-
Mitomycins / adverse effects
-
Prognosis
-
Prospective Studies
-
Random Allocation
-
Stomach Neoplasms / drug therapy*
Substances
-
Mitomycins
-
Cytarabine
-
Mitomycin
-
Fluorouracil